Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.61 |
| ▸ | CCR2 | P41597 | 5/20 | 0.61 |
| ▸ | CCR7 | P32248 | 1/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | CCR4 | P51679 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458902 | 1.00 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL6349226 | 0.97 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL6344586 | 0.94 | CCR2 (0.59) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3458953 | 0.94 | CCR5 (0.62) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3458957 | 0.94 | CCR5 (0.62) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3039360 | 0.91 | CCR5 (0.58) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL6343826 | 0.91 | CCR5 (0.56) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3029085 | 0.91 | CCR2 (0.56) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL6340941 | 0.90 | CCR5 (0.58) | CCR5CCR2CCR7CCR3CCR4 | |
| Hydrochloric Acid SCHEMBL6350443 | 0.90 | CCR5 (0.57) | CCR5CCR2CCR7CCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | claimed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | claimed |
| EP-1889839-B1 | Bicyclic compound, production and use as HIV inhibitors | TOBIRA THERAPEUTICS INC (US) | 2013-11-06 | — | — | EP | claimed |
| EP-1728504-B1 | EMULSION STABILIZER | TAKEDA PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | claimed |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2008-07-03 | — | — | US | claimed |
| EP-1889839-A1 | Bicyclic compound, production and use as HIV inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-02-20 | — | — | EP | claimed |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-1423376-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | claimed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | claimed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| EP-1728505-B1 | PREPARATION WITH ELEVATED CONTENT | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1728505-A1 | PREPARATION WITH ELEVATED CONTENT | Takeda Pharmaceutical Company Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1728504-A1 | EMULSION STABILIZER | Takeda Pharmaceutical Company Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1423376-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003014105-A9 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259876-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | CCR5 1/4885CCR2 3/4885CCR7 17/4885 |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | CCR5 1/4885CCR2 3/4885CCR7 17/4885 |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | CCR5 1/4885CCR2 3/4885CCR7 17/4885 |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | CCR5 1/4885CCR2 3/4885CCR7 17/4885 |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | CCR5 1/4885CCR2 3/4885CCR7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.